Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2021

Open Access 01-04-2021 | Alzheimer's Disease | Original Article

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases

Authors: Mona-Lisa Malarte, Agneta Nordberg, Laetitia Lemoine

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2021

Login to get access

Abstract

Purpose

MK6240 is a second-generation tau PET tracer designed to detect the neurofibrillary tangles in the brains of patients with Alzheimer’s disease (AD). The aim of the study was to characterize 3H-MK6240 in AD and control brain tissue and to compare its binding properties with those of first-generation tau PET tracers.

Methods

Saturation binding assays with 3H-MK6240 were carried out in the temporal and parietal cortices of AD brains to determine the maximum number of binding sites (Bmax) and the dissociation constants (Kd) at these sites. Competitive binding assays were carried out between 3H-MK6240 and unlabelled MK6240, AV-1451 (aka T807, flortaucipir) and THK5117, and between 3H-THK5351 and unlabelled MK6240. Regional binding studies with 3H-MK6240 were carried out in homogenates from six AD and seven control brains and, using autoradiography, on large frozen sections from two AD brains and one control brain.

Results

The saturation binding assays gave Bmax and Kd values of 59.2 fmol/mg and 0.32 nM in the temporal cortex and 154.7 fmol/mg and 0.15 nM in the parietal cortex. The competitive binding assays revealed two binding sites with affinities in the picomolar and nanomolar range shared by 3H-MK6240 and all the tested unlabelled compounds. There were no binding sites in common between 3H-THK5351 and unlabelled MK6240. Regional binding of 3H-MK6240 was significantly higher in AD brain tissue than in controls. Binding in brain tissue from AD patients with early-onset AD was significantly higher than in brain tissue from patients with late-onset AD. Binding of 3H-MK6240 was not observed in off-target regions. Autoradiography showed high regional cortical binding in the two AD brains and very low binding in the control brain.

Conclusions

3H-MK6240 has a high binding affinity for tau deposits in AD brain tissue but also has different binding characteristics from those of the first-generation tau tracers. This confirms the complexity of tau tracer binding on tau deposits with different binding affinities for different binding sites.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nordberg A. Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 2011;3(6):34.CrossRef Nordberg A. Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 2011;3(6):34.CrossRef
2.
go back to reference Golde TE, et al. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123(5):1847–55.CrossRef Golde TE, et al. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123(5):1847–55.CrossRef
3.
go back to reference Villemagne VL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114–24.CrossRef Villemagne VL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114–24.CrossRef
4.
go back to reference Verwilst P, et al. Shedding light on tau protein aggregation: the progress in developing highly selective fluorophores. Chem Soc Rev. 2018;47(7):2249–65.CrossRef Verwilst P, et al. Shedding light on tau protein aggregation: the progress in developing highly selective fluorophores. Chem Soc Rev. 2018;47(7):2249–65.CrossRef
5.
go back to reference Okamura N, et al. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305–16.CrossRef Okamura N, et al. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305–16.CrossRef
6.
go back to reference Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34 Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34
7.
go back to reference Saint-Aubert L, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.CrossRef Saint-Aubert L, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.CrossRef
8.
go back to reference Lemoine L, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.CrossRef Lemoine L, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.CrossRef
9.
go back to reference Lemoine L, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9(1):96.CrossRef Lemoine L, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9(1):96.CrossRef
10.
go back to reference Chiotis K, et al. Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018;45(9):1605–17.CrossRef Chiotis K, et al. Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018;45(9):1605–17.CrossRef
11.
go back to reference Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547(7662):185–90.CrossRef Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547(7662):185–90.CrossRef
12.
go back to reference Lemoine L, et al. Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography. Sci Rep. 2017;7:45496.CrossRef Lemoine L, et al. Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography. Sci Rep. 2017;7:45496.CrossRef
13.
go back to reference Vermeiren C, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33(2):273–81.CrossRef Vermeiren C, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33(2):273–81.CrossRef
14.
go back to reference Brosch JR, et al. Tau imaging in Alzheimer’s disease diagnosis and clinical trials. Neurotherapeutics. 2017;14(1):62–8.CrossRef Brosch JR, et al. Tau imaging in Alzheimer’s disease diagnosis and clinical trials. Neurotherapeutics. 2017;14(1):62–8.CrossRef
15.
go back to reference Perez-Soriano A, et al. PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord. 2017;32(7):1016–24.CrossRef Perez-Soriano A, et al. PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord. 2017;32(7):1016–24.CrossRef
16.
go back to reference Lois C, et al. PET imaging of tau protein targets: a methodology perspective. Brain Imaging Behav. 2019;13(2):333–44.CrossRef Lois C, et al. PET imaging of tau protein targets: a methodology perspective. Brain Imaging Behav. 2019;13(2):333–44.CrossRef
17.
go back to reference Kuwabara H, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877–84.CrossRef Kuwabara H, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877–84.CrossRef
18.
go back to reference Kroth H, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178–89.CrossRef Kroth H, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178–89.CrossRef
19.
go back to reference Declercq L, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58(6):975–81.CrossRef Declercq L, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58(6):975–81.CrossRef
20.
go back to reference Collier TL, et al. cGMP production of the radiopharmaceutical [(18) F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm. 2017;60(5):263–9.CrossRef Collier TL, et al. cGMP production of the radiopharmaceutical [(18) F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm. 2017;60(5):263–9.CrossRef
21.
go back to reference Hostetler ED, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599–606.CrossRef Hostetler ED, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599–606.CrossRef
22.
go back to reference Walji AM, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778–89.CrossRef Walji AM, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778–89.CrossRef
23.
go back to reference Murugan NA, et al. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46(6):1369–82.CrossRef Murugan NA, et al. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46(6):1369–82.CrossRef
24.
go back to reference Aguero C, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.CrossRef Aguero C, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.CrossRef
25.
go back to reference Lohith TG, et al. Brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60(1):107–14.CrossRef Lohith TG, et al. Brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60(1):107–14.CrossRef
26.
go back to reference Pascoal TA, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9): 2818–30. Pascoal TA, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9): 2818–30.
27.
go back to reference Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9(7):1757–67.CrossRef Murugan NA, Nordberg A, Agren H. Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci. 2018;9(7):1757–67.CrossRef
28.
go back to reference Scholl M, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain. 2017;140(9):2286–94.CrossRef Scholl M, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain. 2017;140(9):2286–94.CrossRef
Metadata
Title
Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
Authors
Mona-Lisa Malarte
Agneta Nordberg
Laetitia Lemoine
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-020-05035-y

Other articles of this Issue 4/2021

European Journal of Nuclear Medicine and Molecular Imaging 4/2021 Go to the issue